Abstract
Up-to-date studies have shown that in prostate carcinoma hitherto regarded as resistant to chemotherapy a positive effect can be obtained with docetaxel. In the context of a workshop on chemotherapy in advanced hormone-refractory prostate carcinoma arranged for specialists in internal medicine and in urology, differing opinions on this still new form of therapy were presented and areas of consensus discussed and elaborated, but controversies were also recognized. In the recommendations for therapy suggestions were made for practical implementation (dosage, indications), medications and other means of treatment that can or should be taken/applied at the same time, and monitoring of the treatment and the course of therapy. Particular attention is paid to ascertainment of the effect of therapy and criteria both for a response to treatment, but also for its discontinuation.
| Translated title of the contribution | Treatment of hormone-resistant prostate carcinoma with docetaxel. Indications, preconditions and implementation-conclusions reached at an interdisciplinary experts' workshop held in Berlin on 22-23 July 2005 |
|---|---|
| Original language | German |
| Pages (from-to) | 798-802 |
| Number of pages | 5 |
| Journal | Onkologe |
| Volume | 12 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2006 |